Kim-1 antagonists and use to modulate immune system
CA 2512138 C · Owner: Biogen, Inc. · Inventors: Rennert, Paul D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g. an antigen-presenting cell is disclosed. Such inhibition , is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-.gamma. by lymphocytes or other immune cells in a mammal. Inhibition of IFN-.gamma. is useful for treatment of inflammatory diseases or disorders, e.g. inflammatory bowel disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 29, 2003 and granted July 16, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 29, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 29, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.